Macular degeneration (age-related)- pegaptanib and ranibizumab: Consultee and commentator comments on the ACD
Consultee and commentator comments on the ACD: Novartis Pharmaceuticals Limited (confidential information removed)
Consultee and commentator comments on the ACD: Welsh Assembly Government
Consultee and commentator comments on the ACD: NHS Quality Improvement Scotland
Consultee and commentator comments on the ACD: Derbyshire County Primary Care Trust
Consultee and commentator comments on the ACD: Department of Health, Social Services and Public Safety for Northern Ireland
Consultee and commentator comments on the ACD: Department of Health
Consultee and commentator comments on the ACD: Joint comment from Royal National Institute of the Blind and Macular Disease Society
Consultee and commentator comments on the ACD: Royal College of Ophthalmologists
Consultee and commentator comments on the ACD: Royal College of Nursing
Consultee and commentator comments on the ACD: Pfizer Limited
Consultee and commentator comments on the ACD: Novartis Pharmaceuticals Limited
This page was last updated: 30 March 2010